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Abstract 
Recently many focus study of schizophrenia on gender are about onset and reducing the severity of illness. 
Males typically experience a much earlier age of onset, make up a larger proportion of clinical cases, and are 
more likely to have primary negative symptoms that are associated with chronic course and poor outcome. These 
study used the standard mental state examination of Psychiatry Department of University of North Sumatera, and 
SCID (Structured Clinical Interview for DSM-IV) that had been translated in Indonesian. The psychotic 
symptoms were rated by PANSS, using the total PANSS score. All subjects was examined until 8 weeks for each 
week. From the 80 total subjects, the mean age of the study for males and females was 29,42±5,53 for males and 
30,80±5,64, respectively. The onset was 25,60±6,86 and 26,98±7,44. There was significant difference between 
gender and PANSS total scores in week 1 until 6 (p<0,05) where males was higher than females, but no 
differences in other weeks. The decrease of total PANSS per week showed significant difference (p<0,05) in 
week 1,2, 7 and 8, but not significant in other week. No significant difference (p≥0,05) of total PANSS score 
between gender, before and after using risperidone. The difference respons percentage between male and female 
was not significant (p≥0,05). In these study, the mean dosis of risperidone for male and female respectively was 
4,008±0,141 and 4,083±0,215. There was some significant difference between gender from the psychopathology 
perspective in schizophrenia using risperidone. 
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1. Introduction 
Recently many focus study of schizophrenia on gender are about onset and reducing the severity of 
illness. According to Goldstein and Lewine, males with schizophrenia generally have an earlier onset of illness 
and a more severe form of the disease as reflected in greater cognitive or social impairment, while female 
patients are more likely to suffer from anxiety and affective symptoms (Choi, Chon, Kang, Jung and Kwon, 
2009). 
Males typically experience a much earlier age of onset, make up a larger proportion of clinical cases, 
and are more likely to have primary negative symptoms that are associated with chronic course and poor 
outcome (Thaker, 2009). In the Netherlands study, younger age, living in an urban environment, low income, 
less education, unemployment, female gender, and being single were all associated with increased rates of 
hallucinations (Lewis, Escalone and Keith, 2009). 
The risk of developing schizophrenia is similar in males and females; however, the sex of the patient 
plays an important role in the clinical manifestation of the disorder. Cross-sectional studies generally find that 
the symptoms of schizophrenia fall into three independent clusters: positive psychotic symptoms (or reality 
distortion), disorganization in thought and behavior, and negative symptoms. These symptom clusters wax and 
wane over the course of the illness, are independent of one another, and often respond differentially to treatment 
with antipsychotic agents. Symptoms of reality distortion are most amenable to antipsychotic drug treatment, 
followed by disorganized thinking and behavior (Thaker, 2009). 
Positive and negative symptoms were facilitated by the creation of reliable and valid rating scales such 
as the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Negative Symptoms, 
and the Scale for the Assessment of Positive Symptoms (SAPS) (Lewis, Escalone and Keith, 2009).  As in the 
CATIE trial, CUtLASS 1 (Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study) found no 
advantage for SGAs (second- generation antipsychotics) in terms of PANSS total and positive subscale scores 
(Miyamoto, Merill, Lieberman, Fleischacker and Marder, 2008). However, these study tried to learn about 
gender difference on PANSS total score using SGA, risperidone. 
The preferential use of SGAs over FGAs is now common in the treatment of first-episode patients 
because of their generally lower EPS burden and possible superiority in relapse prevention. It has also been 
hypothesized that the glutamatergic effects of some SGAs may provide a neuroprotective function, potentially 
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resulting in better long-term outcomes (Miyamoto, Merill, Lieberman, Fleischacker and Marder, 2008). Also the 
impact on overweight, elevated serum cholesterol and elevate prolactin levels, which can result in galactorrhea 
and irregular menses (Newcomer, Fahnestock and Haupt, 2009; Kane, Stroup and Marder, 2009). Mortality was 
significantly higher in men than in women, and the difference was primarily due to an excess of male suicides 
and accidents (Jablensky, 2009). 
Risperidone has substantially higher affinity for 5-HT 2A and D 2 receptors than does clozapine. A PET 
study found that risperidone occupies 75–80% of striatal D 2 receptors and 78–88% of cortical 5-HT 2 receptors 
when administered to schizophrenic patients at a dose of 6 mg/day. Despite high levels of D 2 receptor 
occupancy, moderate-dose risperidone treatment (4–6 mg/day) poses a somewhat lower EPS risk than treatment 
with some FGAs. This may be due to the 5-HT 2A antagonistic properties of the drug (Miyamoto, Merill, 
Lieberman, Fleischacker and Marder, 2008). Risperidone also the first antipsychotic that given monotherapy as 
24.5%, followed by olanzapine (20.3%), sulpiride (14.6%), quetiapine (12.5%) or haloperidol (9.4%). As the 
antipsychotics that showed the highest rates of use in polytherapy were olanzapine (37.1%), oral risperidone 
(36.4%), quetiapine (29.3%), haloperidol (27.9%), levomepromazine (26.5%) and clotiapine (21.9%) (Bernardo, 
Coma, Ibanez, Zara, Bari and Serrano-Blanco, 2012). 
Women are generally more emotionally involved with their friends and families than are men, and 
effective treatment must take interpersonal stressors into greater account (Seeman, 2008). Atalayu in 2006 
reported that women with schizophrenia have better social functioning than men (Atalay and Atalay, 2006). But 
Carpiniello et.al in 2011 with define clinical remission (scores less than or equal to 3 for all PANSS items), said 
no difference was found between genders (Carpiniello, Pinna, Tusconi, Zaccheddu and Fatteri, 2012). According 
to most of the studies revised, one possible explanation of this better adjustment could be that women presented 
a higher age of onset than men, which allows them to adjust better to the requirements of the community (Ochoa, 
Usall, Cobo, Labad and Kulkarni, 2012). 
Mental Hospital of Province of North Sumatera had 70% paranoid schizophrenia patients as first and 
recurrent was 46,7% and 53,3%, by Hutagalung, 2009 (Hutagalung, 2009). We study first episode paranoid 
patients using risperidone as first line antipsychotic in that hospital. We compared the total PANSS between male 
and female. 
 
2. Subject and Methods 
This study was approved by the Research Ethics Committee of Medical Faculty University of Sumatera Utara. 
This study was performed in Mental Hospital of Province of North Sumatera, on the regulation of Medical 
Faculty of University of North Sumatera, from April-November 2013. Subject from the outpatient care, with first 
episode paranoid schizophrenia using risperidone. These study was two group pretest-posttest design, open 
trial,with consecutive sampling. The criteria inclusion was 15-55 years old, ideal body mass index and 
cooperative. We exclude the organic mental disorder, hypersensitivity with risperidone, pregnancy, using 
contrasepsi and heavy smoke (more than 5 ciggarettes for more than 2 years) (Waked, Khayat and Salameh, 
2012). 
 
2.1 Assessment and Rating 
These study used the standard mental state examination of Psychiatry Department of University of North 
Sumatera, and SCID (Structured Clinical Interview for DSM-IV) that had been translated in Indonesian. The 
psychotic symptoms was rated by PANSS, using the total PANSS score. All subjects was examined until 8 weeks 
for each week. 
 Treatment would be given if there was any side effects, such as extrapyramidal symptoms. If the 
subjects was stop or never come back into these study, the last week of total PANSS score were used (LOCF-
Last Observation Carried Forward). 
 
2.2 Statistical Analysis 
Univariat analysis was performed to describe each variable and was described by frequency table. The statistical 
analysis were assessed by T-test for the independent sample, using SPSS 15.5. A significant level was considered 
as 5%. 
 
3. Result 
Demographic characteristics of participants are illustrated in Table 1.  
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Table 1. Demographic characteristics 
No Variabel Males  Females p 
1 
 
 
 
 
 
2 
3 
Age (means+SD) years  
             < 20 
                20-29 
                30-39 
               40-49 
             >50 
onset (means+SD) years 
BMI (rerata+SD) 
29,42 + 5,53 
0 
22 (55%) 
16 (40%) 
1 (2,5%) 
1 (2,5%) 
25,60 + 6,86 
22,07 + 0,97 
30,80 + 5,64 
1 (2,5%) 
12 (30%) 
18 (45%) 
9 (22,5%) 
0 
26,98 + 7,44 
22,32 + 1,19 
0,27 
 
 
 
 
 
0,39 
0,31 
 
From the 80 total subjects, the mean age of the study for males and females was 29,42±5,53 for males and 
30,80±5,64, respectively. The onset was 25,60±6,86 and 26,98±7,44. The body mass index was 22,07±0,97 and 
22,32±1,19. From tabel 1, the difference of age, onset and BMI was not significant. 
 
Table 2. Difference between gender and PANSS total score 
 
Total PANSS  
 
Weeks Males  Females P 
0 (before) 
1 
2 
3 
4 
5 
6 
7 
8 
84,78 + 3,00 
76,63 + 5,83 
70,45 + 8,36 
64,00 + 9,62 
58,55 + 10,71 
52,52 + 11,22 
48,33 + 10,71 
45,55 + 10,41 
43,92 + 9,70 
84,08 + 3,94 
72,35 + 6,65 
64,22 + 8,66 
57,08 + 10,30 
51,35 + 11,49 
46,33 + 9,59 
42,85 + 8,11 
41,88 + 8,02 
41,35 + 7,91 
0,37 
0,001* 
0,001* 
0,001* 
0,001* 
0,01* 
0,01* 
0,08 
0,20 
            * t-test 
 
From tabel 2, there was significant difference between gender and PANSS total scores in week 1 until 6 (p<0,05) 
where males was higher than females, but no differences in other weeks. 
 
Table 3. Decrease of total PANSS score 
 Total PANSS decrease  
Week Male Female P 
1 
2 
3 
4 
5 
6 
7 
8 
-8,15 ± 4,95 
-6,17 ± 3,93 
-6,45 ± 3,77 
-5,45 ± 4,08 
-6,03 ± 4,62 
-4,20 ± 4,04 
-2,77 ± 3,47 
-1,63 ± 3,17 
-11,73 ± 6,32 
-8,13 ± 4,2 
-7,15 ± 4,63 
-5,72 ± 4,03 
-5,03 ± 4,64 
-3,48 ± 3,78 
-0,98 ± 1,70 
-0,53 ± 1,13 
0,01* 
0,03* 
0,46 
0,76 
0,34 
0,41 
0,001* 
0,04* 
               * t-test 
 
The decrease of total PANSS per week in table 3, showed significant difference (p<0,05) in week 1,2, 7 and 8, 
but no significant in other week. 
 
Table 4. Total PANSS score between gender with risperidone  
Total PANSS decrease Male Female 
Before (week 0) 84,78±3,00 84,08 + 3,94 
After (week 8) 43,92 ± 9,69 41,35 + 7,91 
Decrease (before-after) -40,85 + 8,98 -42,75 +9,11 
       * t-test, p=0,357 
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From table 4. There is no significant difference (p≥0,05) of total PANSS score between gender, before and after 
using risperidone. 
 
Table 5. Respons using risperidone 
Respons Percentage Male(%) Female(%) 
Week 1 5 17,5 
Week 8 97,5 100 
     * Chi square, p= 0,300 
 
The difference respons percetage between male and female was not significant (p≥0,05). In these study, the mean 
dosis of risperidone for male and female respectively was 4,008±0,141 and 4,083±0,215. 
 
Tabel 6. Inter-rater 
Spearman *) p **) 
Week 0 (before) 0,672-1,000 0,01 
Week 1 0,806-1,000 0,01 
Week 8 0,768-1,000 0,01 
*) Spearman correlation test 
**) 2 tailed 
From table 6 showed significant correlation (p<0,05) between rater and the inter-rater. 
 
4. Discussion 
The present study provided a two group pretest-posttest design, open trial with consecutive sampling. From the 
first week, risperidone have had a significant difference between gender for the total PANSS score and the 
decrease of the total PANSS. For the first week males where significant higher than females (76,63 + 5,83 vs 
72,35 + 6,65, p<-0,05) with the decrease of PANSS score also females significant higher than males (-8,15 ± 
4,95 vs -11,73 ± 6,32, p<0,05). This study was different with Nawka et. al, 2013 using BPRS where females was 
higher significant than males (58,9±14,5 vs 54,6±14,0). These difference may because the Nawka study subjects 
consisted difference diagnosis where mainly patients with paranoid schizophrenia (with slight prevalence of 
men) and residual schizophrenia (with slight prevalence of women) (Nawka, Kalisova, Raboch, Giacco, Cihal, et 
al, 2013). These result also may be explained by neurodevelopment theory of gender. Lenroot et. al, 2007 said 
that the male brain is larger than the female brain across all the stages of development, and certain structures 
within the brain differ in size in males and females (Kleinhaus, Harlap, Perrin, Manor, Weiser, et al, 2011). 
Labelle et.al, 2001 found there was no significant difference total PANSS score over 8 weeks study, 
where the mean decease of PANSS for males and females was -23,1 and 21,6 (p>0.05). The difference with the 
present study that Labelle used chronis and subchronis schizophrenia as for DSM-III-R. But these two study also 
found no significant difference between gender for the response with risperidone over 8 weeks. Also they found 
no significant difference in the mean final dosage of risperidone, where the mean final dosage was 6,1 mg in 
male and 6,2 mg in female participants (Labelle, Light and Dunbar, 2001). 
These significant difference between males and females in these study may be because the estrogen 
hormon with the antidopaminergic effects, give women the better response to antipsychotic (Kulkarni, 2009). 
Estrogens modulate the neurotransmitters responsible for cognitive and emotional processes. For example, 
estrogens reduce dopamine receptor sensitivity and increase D2 receptor density in the striatum of ovariec-
tomised rats, while also significantly enhancing serotonergic neurotransmission. Its effects on mental state are 
thought to occur via an influence on the availability of these mood-relevant neurotransmitters in the synapse 
(Kulkarni, Gavrilidis, Worsley, Rheenen and Hayes, 2013). In Kulkarni et.al, 2010 trial in 53 men with 
schizophrenia was conducted to evaluate the efficacy of 2 mg oral estradiol valerate as an adjunct to atypical 
antipsychotic treatment, had demonstrated for estradiol participants a more rapid reduction in general 
psychopathology that occurred in the context of greater increases in serum estrogen levels and reductions in FSH 
and testosterone levels (Kulkarni, Castella, Headey, Marston, Sinclair, et al, 2011). 
For the difference between gender, Wilhite et.al, 2008 found that Male and female participants did not 
vary significantly in any relevant demographic variables, including age. The absence of an age difference in our 
clinical population could be explained by a variety of reasons. Female may have a longer prodromal period than 
males (i.e. males may experience a faster deterioration once subthreshold psychotic symptoms arise). 
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Additionally, some recent studies have suggested that the age of onset differences may only exist in certain kinds 
of psychosis, namely among those patients who develop paranoid schizophrenia (Wilhite, Niendam, Bearden, 
Zinberg, O’Brien and Cannon, 2008). 
Also Jaaskelainen et.al, 2013 said that there were no statistically significant differences when the 
estimates were stratified according to sex, midpoint of intake period, strictness of the diagnostic criteria, duration 
of follow-up, or other design features. They suggested major changes in treatment option, because the proportion 
of recovered cases has not increased (Jaaskelainen, Juola, Hirvonen, McGrath, Saha, Isohanni et. Al, 2013). 
Genetic study about gender by Feng et.al, 2009 found  that functional analyses of ectopically expressed 
copies of the variant miRNA precursors demonstrate loss of function, gain of function or altered expression 
levels. They study suggests that microRNA mutations can contribute to schizophrenia (Feng, Sun, Yan, Noltner, 
Li et. al) 
 
5. Conclusion and Limitation 
There was some significant difference between gender from the psychophatology perspective in 
schizophrenia using risperidon. The significant difference of PANSS score was on week 1 and 6, where males 
was greater than females. The decrease of PANSS score also had significant difference where on week 1 and 2, 
feremales had higher decrease than females, but in week 7 and 8. The difference before and after 8 weeks using 
risperidone has no significant difference. Also the response treatment between males and females had no 
significant difference. 
The limitation of these study was smoking behavior that just get from the interview (i.e. <5 cigarette, 2 
years). The adherence also been considered. As Julius et.al said that there’s three factore of adherence: 
medication-related risk factors, psychological risk factors, and social/environmental risk factors. Then Maguro, 
et.al 2011 said Identifying predictors of medication adherence among patients with dual psychiatric and 
substance misuse problems is important because poor adherence is associated with relapse and re-hospitalization 
(Magura, Rosenblum and Fong, 2011). 
The suggestion was on demographic factors and smoking behavior of the schizophrenia study. Also 
more study on the pre-psychotic, recurrent schizophrenia and each phase of treatment. The comparasion of 
neuroimaging of schizophrenia have been interested, as well as the neurodevelopmental study, estrogen hormon 
and genetic. 
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